Registration for a live webinar on 'Phasing Out Animal Testing: A New Era for Pharmaceutical Innovation' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and Risk Factors
-
1. Coronary heart disease epidemiology: global context for a new genetic understanding
- Prof. Harry Hemingway
-
2. Cardiovascular risk factors
- Dr. Michal Vrablik
-
3. Lipoproteins
- Prof. Arnold von Eckardstein
-
4. Thrombotic risk factors for cardiovascular disease
- Prof. Gordon Lowe
-
5. Lipoprotein(a)
- Dr. Jaimini Cegla
- Biology of Coronary Heart Disease
-
6. Plaque rupture
- Prof. Petri Kovanen
-
7. Transcription factors and complex disease development
- Dr. Ines Pineda-Torra
-
8. Animal models to explore cardiovascular disease
- Prof. Martin Merkel
- Treatment
-
9. Diagnosis and treatment of dyslipidemias
- Prof. Anton Stalenhoef
-
10. Key drug discovery challenges in cardiovascular medicine
- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Genetics
-
11. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
12. Heart disease genes and SNPs
- Prof. Steve Humphries
-
13. Familial hypercholesterolaemia: genetic causes and treatment
- Prof. Steve Humphries
-
14. Familial hypercholesterolaemia: cascade testing and monogenic vs. polygenic causes
- Prof. Steve Humphries
-
16. Genetics of cardiovascular disease
- Prof. Philippa Talmud
-
17. The genetics of CHD: moving research findings into patient benefit
- Prof. Steve Humphries
-
19. The genetics of abdominal aortic aneurysm
- Dr. Seamus Harrison
-
20. Genome scans for hypertension
- Prof. Patricia Munroe
-
21. Telomeres and cardiovascular disease
- Dr. Jess Buxton
-
23. Genetics of hypertrophic cardiomyopathy (HCM)
- Dr. Petros Syrris
- Archived Lectures *These may not cover the latest advances in the field
-
24. Gene-environment interaction and oxidative stress in cardiovascular disease
- Dr. Jeffrey Stephens
-
25. Gene therapy as a therapeutic option for lipoprotein lipase deficiency
- Dr. Jan Albert Kuivenhoven
-
26. Cardiovascular diseases: from epidemiology to nutritional interventions
- Dr. Antonis Zampelas
-
27. Genetic testing for CHD risk: fact or fiction?
- Prof. Steve Humphries
-
28. Pharmacogenetics: progress, pitfalls and clinical potential
- Prof. Steve Humphries
-
29. Familial hyperchlolesterolaemia: a monogenic cause of early CHD
- Prof. Steve Humphries
-
30. Lipid metabolism
- Dr. Ulrike Beisiegel
Printable Handouts
Navigable Slide Index
- Introduction
- Primary dyslipidemias
- Structure of lipoproteins
- Physicochemical properties of lipoproteins
- Lipoprotein classes and atherosclerosis
- Autosomal dominant hypercholesterolemia
- Autosomal recessive hypercholesterolemia
- Primary dyslipidemias
- Familial hypercholesterolemia pedigree
- Metabolic abnormality in FH
- The attribute of sex to coronary death
- Typical xanthomas
- Atherosclerosis recognition by Bmode ultrasound
- Thin intima vs. thick intima
- Diagnosis of FH
- Pharmacotherapy
- Mechanism of action of statins
- Increase in the synthesis of hepatic LDL receptors
- Niacin
- Dual inhibition
- Hypolipidemic drug therapy
- Case FH
- Case FH: LDL-c lowering after combined treatment
- FH - current situation
- Tracing FH patients
- Familial combined hyperlipidemia
- FCH prevalence
- 1973 FCH definition
- FCH pedigree
- Lipid and lipoprotein levels in FCH
- Lipoprotein particle size
- Associated CHD risk with an apoB increase
- Insulin resistance in FCH
- Values for prediction of FCH
- Therapy FCH
- Hypertriglyceridemia treatment
- Familial hypertriglyceridemia
- TG levels after treatment
- TG concentration and production
- Triglycerides variation in serum
- Cholesterol and triglycerides elevated
- Familial dysbetalipoproteienemia
- Palmar streaks in FD
- Tubero eruptive xanthomas in FD
- Apolipoprotein E isoforms
- Pedigree of index-patient and family members
- ApoE type and frequencies in the Netherlands
- Cholesterol levels in apoE2/E2
- Aggravating factors
- Lipid values in FD patients
- Reduced penetrance
- Clinical diagnosis
- Secondary dyslipidemias
- Secondary forms of HLP
- Lipemia retinalis
- Appearance of plasma before and after treatment
Topics Covered
- Primary dyslipidemias
- Autosomal dominant and recessive hypercholesterolemia
- Familial hypercholesterolemia
- Familial combined hyperlipidemia
- Familial hypertriglyceridemia
- Familial dysbetalipoproteinemia
- Pharmacotherapy
- Secondary dyslipidemias
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stalenhoef, A. (2008, November 24). Diagnosis and treatment of dyslipidemias [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 21, 2025, from https://doi.org/10.69645/MNTX4025.Export Citation (RIS)
Publication History
- Published on November 24, 2008
Financial Disclosures
- Prof. Anton Stalenhoef has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.